Concert Pharmaceuticals Profit Margin

Concert Pharmaceuticals (CNCE) currently reports a profit margin of -117455.64% as of September 2022. That compares with -203.59% in the prior-year period — down 57593.4% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Concert Pharmaceuticals's profit margin history and peer comparisons.

Concert Pharmaceuticals's profit margin decreased from -203.59% to -117455.64% — a 57593.4% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Concert Pharmaceuticals's profit margin of -117455.64% is lower than the Healthcare sector average of 21.34%. That is roughly 550625.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Concert Pharmaceuticals's current -117455.64% should be judged against Healthcare norms (sector average: 21.34%) and against CNCE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -117455.64%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Concert Pharmaceuticals, and consider following CNCE for alerts when major investors trade the stock.